Get the Stockscreener App
84.86
1.78%
1.48
After Hours:
86.54
1.68
+1.98%
Nuvalent Inc stock is traded at $84.86, with a volume of 291.27K.
It is up +1.78% in the last 24 hours and up +6.30% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$83.38
Open:
$83.95
24h Volume:
291.27K
Relative Volume:
0.66
Market Cap:
$5.66B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-21.76
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+2.76%
1M Performance:
+6.30%
6M Performance:
+43.05%
1Y Performance:
-17.13%
1-Day Range:
$82.50
$85.38
1-Week Range:
$81.02
$86.34
52-Week Range:
$55.53
$106.32
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
84.86 | 6.01B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
The Escalator: Eli Lilly, Nuvalent, Lumen Bioscience and more - Medical Marketing and Media
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year By Investing.com - Investing.com South Africa
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating - 富途牛牛
Is Nuvalent Inc. stock a buy before product launchesMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
Can trapped investors hope for a rebound in Nuvalent Inc.Risk Management & Long-Term Safe Investment Ideas - newser.com
How Nuvalent Inc. stock reacts to oil pricesWeekly Trade Report & Community Shared Stock Ideas - newser.com
Intraday pattern recognizer results for Nuvalent Inc.2025 Dividend Review & Community Shared Stock Ideas - newser.com
What to expect from Nuvalent Inc. in the next 30 daysJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Will Nuvalent Inc. stock outperform Dow Jones index2025 Key Lessons & AI Driven Price Predictions - newser.com
Is Nuvalent Inc. reversing from oversold territoryQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
Analyzing net buyer seller activity in Nuvalent Inc.Quarterly Risk Review & Free Expert Approved Momentum Trade Ideas - newser.com
Nuvalent, Inc. Stock (NUVL) Opinions on Cancer Therapy Developments and Insider Sale - Quiver Quantitative
Nuvalent chief development officer Noci sells $332k in shares By Investing.com - Investing.com Australia
Nuvalent CFO Balcom sells $2.3m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent chief development officer Noci sells $332k in shares - Investing.com India
Nuvalent CFO Balcom sells $2.3m in NUVL stock - Investing.com
Transcript : Nuvalent, Inc. Presents at UBS Virtual Oncology Day, Oct-01-2025 03 - MarketScreener
Can you recover from losses in Nuvalent Inc.Buy Signal & Weekly Stock Performance Updates - newser.com
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely - 富途牛牛
Price action breakdown for Nuvalent Inc.Market Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Is Nuvalent Inc a good long term investmentEvening Star Patterns & Free Get High Potential Alerts - Early Times
What analysts say about Nuvalent Inc stockSupport Level Holds & Superior Portfolio Investment - earlytimes.in
What drives Nuvalent Inc stock priceRetail Investor Activity & Exceptional Profit Trading - earlytimes.in
Is this a good reentry point in Nuvalent Inc.2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Barclays Keeps Their Buy Rating on Nuvalent (NUVL) - The Globe and Mail
Barclays Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Balcom Alexandra | Chief Financial Officer |
Oct 01 '25 |
Sale |
85.48 |
20,000 |
1,709,512 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 30 '25 |
Option Exercise |
6.89 |
20,000 |
137,800 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 29 '25 |
Option Exercise |
6.89 |
7,588 |
52,281 |
69,322 |
| Balcom Alexandra | Chief Financial Officer |
Sep 30 '25 |
Sale |
85.06 |
20,000 |
1,701,200 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 29 '25 |
Sale |
85.01 |
7,588 |
645,056 |
61,734 |
| Noci Darlene | Chief Development Officer |
Sep 29 '25 |
Option Exercise |
27.85 |
4,000 |
111,400 |
52,034 |
| Noci Darlene | Chief Development Officer |
Sep 29 '25 |
Sale |
83.07 |
4,000 |
332,288 |
48,034 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):